Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis
European Heart Journal - Cardiovascular Imaging · 2024
DOI: 10.1093/ehjci/jead344 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal - Cardiovascular Imaging, 2024. Verfasst von Rosy Haruna Nishizawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences,1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles, Echocardiography. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Aims
Although tafamidis is used in patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), its specific effect on cardiac function is unclear. Thus, this study aimed to investigate the effect of tafamidis on left atrial (LA) and left ventricular function using speckle-tracking echocardiography for 1 year of treatment in patients with ATTRwt-CA. Methods and results We included 23 patients (mean age, 76 years) with ATTRwt-CA confirmed via biopsy. We analysed the left ventricular and LA strain using 2D speckle-tracking echocardiography and compared these parameters before and 1 year after starting treatment with tafamidis between 16 patients with sinus rhythm (SR) and 7 patients with atrial fibrillation (AF). In ATTRwt-CA patients with SR, LA reservoir strain significantly improved by 1-year tafamidis treatment (10.5 ± 5.0% to 11.9 ± 5.3%, P = 0.0307) although global longitudinal strain (GLS) did not (−10.6 ± 3.1% to −11.3 ± 3.0%, P = 0.0608). In contrast, LA reservoir strain was not significantly changed (5.4 ± 2.9% to 4.9 ± 1.7%, P = 0.4571), and GLS deteriorated (−8.4 ± 2.3% to −6.8 ± 1.4%, P = 0.0267) in ATTRwt-CA patients with AF.
Conclusion
LA function improved with tafamidis treatment in ATTRwt-CA patients with SR but not left ventricular function. However, these cardiac functions did not improve with tafamidis treatment in ATTRwt-CA patients with AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences,1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
- Ultrasound Imaging Center, Nagasaki University Hospital, Nagasaki, Japan.
- Department of Pathology, Nagasaki University Hospital, Nagasaki, Japan.
- Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Hiroaki Kawano, Satoshi Ikeda, Koji Maemura
Zitieren
APA
Nishizawa, R. H., Kawano, H., Yoshimuta, T., Eguchi, C., Kojima, S., Minami, T., Sato, D., Eguchi, M., Okano, S., Ikeda, S., Ueda, M., & Maemura, K. (2024). Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging. https://doi.org/10.1093/ehjci/jead344
Vancouver
Nishizawa RH, Kawano H, Yoshimuta T, Eguchi C, Kojima S, Minami T, et al. Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging. 2024. doi:10.1093/ehjci/jead344
BibTeX
@article{Nishizawa2024,
author = {Nishizawa, Rosy Haruna and Kawano, Hiroaki and Yoshimuta, Tsuyoshi and Eguchi, Chisa and Kojima, Sanae and Minami, Takako and Sato, Daisuke and Eguchi, Masamichi and Okano, Shinji and Ikeda, Satoshi and Ueda, Mitsuharu and Maemura, Koji},
title = {Effects of tafamidis on the left ventricular and left atrial strain in patients with wild-type transthyretin cardiac amyloidosis},
journal = {European Heart Journal - Cardiovascular Imaging},
year = {2024},
doi = {10.1093/ehjci/jead344}
}
EUVIMED